Vasculitis
Vasculitis is a complex group of autoimmune diseases characterized by inflammation of blood vessels, leading to tissue damage and organ dysfunction. At our company, we are committed to advancing the field of vasculitis research through our comprehensive drug and therapy development services.
Introduction to Vasculitis
Vasculitis refers to a spectrum of disorders characterized by inflammation of blood vessels of varying sizes. The pathogenesis of vasculitis involves an immune-mediated attack on blood vessel walls, leading to vessel wall damage, impaired blood flow, and tissue injury. The pathogenesis of vasculitis involves dysregulation of the immune system, leading to the activation of inflammatory cells and the production of autoantibodies. This immune response targets the blood vessel walls, resulting in endothelial cell dysfunction and subsequent inflammatory infiltrates.
- Types of Vasculitis
-Buerger disease
-Behcet's disease
-Cryoglobulinemia-Churg-Strauss syndrome
-Giant cell arteritis
-Granulomatosis with polyangiitis-Takayasu's arteritis
-Kawasaki disease
-Henoch-Schonlein purpura
Fig.1 Histopathological findings in leukocytoclastic vasculitis (LCV). (Fraticelli P., et al., 2021)
Drug Discovery and Development for Vasculitis
Immunosuppressive agents, such as methotrexate, azathioprine, or mycophenolate mofetil, play a vital role in maintaining disease control and reducing the cumulative dose of glucocorticoids. With advances in understanding the underlying immunopathology of vasculitis, targeted biologic agents have emerged as promising therapeutic options. These agents specifically inhibit key molecules or pathways involved in the pathogenesis of vasculitis, providing a more precise and tailored approach to therapeutics. Biologic agents, such as rituximab (anti-CD20 monoclonal antibody) or tocilizumab (IL-6 receptor antagonist), have shown promising results in specific subtypes of vasculitis and are actively being investigated in clinical trials.
With our company's comprehensive range of therapeutic development platforms, whether it is immunotherapy for vasculitis or the development of targeted agents, we can meet your requirements. Please click on the link below to learn more.
Our Services
At our company, we are dedicated to providing comprehensive services for the development of vasculitis diagnostics and therapies. In addition, our company offers a wide range of preclinical research services, including pharmacokinetic and pharmacodynamic studies, toxicity assessments, and efficacy evaluations. Through rigorous testing and analysis, we aim to identify promising drug candidates and optimize their formulation and delivery strategies.
Spontaneous Vasculitis Models
The Brown Norway rat, which develops necrotizing vasculitis upon exposure to mercuric chloride, serves as a critical model for investigating ANCA-associated vasculitis.
Induced Vasculitis Models
We utilize bovine serum albumin to induce serum sickness in rabbits, a model that closely mirrors immune complex-mediated vasculitis.
Genetically Engineered Models
We develop transgenic mice expressing human ANCA targets, providing a platform to study the direct effects of these antibodies on vasculitic pathology.
Chronic Infection Vasculitis Models
Developing models using viral infections to induce vasculitis, providing insights into the mechanisms by which infections contribute to vasculitic processes.
Primary endothelial cells derived from human blood vessels are utilized to study the direct effects of ANCA on vascular inflammation. In addition, our company specializes in the development of co-culture systems.
We develop vascular organoids that mimic the structure and function of blood vessels. These organoids provide a platform for studying the early stages of vasculitis and the response to therapeutic agents.
Our state-of-the-art facilities and experienced team of researchers enable us to offer a wide range of services tailored to meet the specific needs of our clients. In addition to the aforementioned services and models, we also provide customized solutions and develop disease models that cater specifically to your unique needs. If our services have piqued your interest, please do not hesitate to contact us.
Reference
- Fraticelli P., et al. "Diagnosis and management of leukocytoclastic vasculitis." Internal and emergency medicine 16.4 (2021): 831-841.